Cutler Group LP Cure Vac N.V. Call Options Transaction History

Cutler Group LP

12 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 Apr 19, 2024	SELL	$2.94 - $4.34 $1,764 - $2,604	-600 Reduced 5.66%	10,000 $0
Q4 2023 Jan 18, 2024	BUY	$3.96 - $6.41 $39,600 - $64,100	10,000 Added 1666.67%	10,600 $4,000
Q1 2023 May 01, 2023	SELL	$6.38 - $12.5 $10,846 - $21,250	-1,700 Reduced 73.91%	600 $0
Q3 2022 Oct 25, 2022	BUY	$7.48 - $15.24 $2,244 - $4,572	300 Added 15.0%	2,300 $0
Q2 2022 Aug 04, 2022	BUY	$13.18 - $19.41 $1,318 - $1,941	100 Added 5.26%	2,000 $1,000
Q1 2022 Apr 14, 2022	SELL	$14.73 - $35.25 $334,371 - $800,175	-22,700 Reduced 92.28%	1,900 $1,000
Q4 2021 Jan 18, 2022	BUY	$33.72 - $48.22 $698,004 - $998,154	20,700 Added 530.77%	24,600 $85,000
Q3 2021 Oct 26, 2021	SELL	$49.26 - $74.5 $2.42 Million - $3.66 Million	-49,100 Reduced 92.64%	3,900 $11,000
Q2 2021 Jul 19, 2021	BUY	$56.91 - $127.53 $2.44 Million - $5.47 Million	42,900 Added 424.75%	53,000 $426,000
Q1 2021 Apr 26, 2021	SELL	$79.79 - $126.29 $1.18 Million - $1.87 Million	-14,800 Reduced 59.44%	10,100 $101,000
Q4 2020 Jan 21, 2021	BUY	$46.76 - $136.27 $299,264 - $872,128	6,400 Added 34.59%	24,900 $87,000
Q3 2020 Oct 27, 2020	BUY	$43.8 - $77.2 $810,300 - $1.43 Million	18,500 New	18,500 $33,000

12.3M

164K

117K

Ticker CVAC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,467,008
Market Cap $499M
Description
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.